Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01677065 · ClinicalTrials.gov registry record
A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers
A clinical trial of Healthy, sponsored by Pfizer.
- Completed
- Registry status
- 14
- Enrollment target
- 1
- Study location
NCT01677065: Completed study of Healthy, sponsored by Pfizer.
NCT01677065 is a study of Healthy that has completed, run by Pfizer. The registered enrollment target is 14 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01677065, a study of Healthy, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine whether the bioavailability of the controlled-release test formulation is at least as high as that for the commercial reference drug.
Conditions Studied
Interventions
- DRUG Oxycodone controlled-release test formulation
- DRUG Immediate-release reference drug
Study Locations (1)
Connecticut
- Pfizer Investigational Site - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-09 |
| Est. Completion | 2012-10 |
What the finished NCT01677065 record still lists
NCT01677065 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Oxycodone controlled-release test formulation is the first listed.
NCT01677065 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT01677065 about?
NCT01677065 is a clinical study titled "A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers". To determine whether the bioavailability of the controlled-release test formulation is at least as high as that for the commercial reference drug.
What is the current status of trial NCT01677065?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2012-09. Estimated completion is 2012-10.
What conditions does trial NCT01677065 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT01677065?
The interventions under investigation include: Oxycodone controlled-release test formulation (DRUG), Immediate-release reference drug (DRUG).
Who is sponsoring clinical trial NCT01677065?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01677065 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01677065's enrollment target sits among peer trials
14 974th of 1090 higher than 106 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mapping Auricular Vagus Nerve Circuitry
RECRUITING · Early Phase 1
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
The Modulatory Effect of Female Sex Hormones on Spinal Neuroplasticity
RECRUITING
-
Breathing & Blood Pressure
RECRUITING
-
Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 1
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia